The Differential Expression Of LncRNA BCAR4 In Locally Advanced Breast Cancer And It’s Correlation With The Efficacy Of Neoadjuvant Chemotherapy

Objective:To explore the differences in the expression of LncRNA BCAR4 in cancer tissues and unpaired normal tissues of locally advanced breast cancer patients beforechemotherapy,and its correlation with the clinical efficacy of neoadjuvant chemotherapy RECIST 1.1,Miller Payne efficacy and histopathological efficacy,and to study whether LncRNA BCAR4 can be used as a predictor Factors in the efficacy of neoadjuvantchemotherapy for locally advanced breast cancer.Method:1.Bioinformatics analysis of LncRNA BCAR4 expression and correlationanalysis:Through TCGA database,the differential expression of LncRNA BCAR4 in 33kinds of malignant tumors was analyzed,and the relationship between its expression level and the survival prognosis of breast cancer patients,as well as its correlation with tumor mutation load and microsatellite instability.2.Detection of LncRNA BCAR4 expression differences in patient tissues:Inclusion and exclusion criteria were set.Patients with locally advanced breast cancer were screened for inclusion.Paraffin puncture tissues and normal breast tissues of patients were collected before chemotherapy,and the expression of LncRNA BCAR4 was detected by q PCR.The expression of LncRNA BCAR4 was statistically correlated with age,tumor size,molecular typing,hormone receptor status,HER-2 status,and Ki-67 expression of enrolled patients.3.Efficacy evaluation and grouping of patients with neoadjuvant chemotherapy:Theenrolled patients were evaluated for efficacy of neoadjuvant chemotherapy through three efficacy evaluation systems,and the patients were divided into effective group andineffective group under each evaluation system.4.Statistical analysis of the correlation between the expression of LncRNA BCAR4 and the efficacy of neoadjuvant chemotherapy:Independent sample t test was used to analyze the expression difference of LncRNA BCAR4 between cancer and unpaired normaltissues;Classification variables were tested by?~2,and rank sum test was used to analyze the correlation between the expression level of LncRNA BCAR4 and clinicopathological data characteristics of enrolled patients.Multivariate Logistic regression was used toanalyze the factors influencing the efficacy of neoadjuvant chemotherapy in locally advanced breast cancer.P<0.05 was considered statistically significant.Result:1.TCGA database analysis found that LncRNA BCAR4 is significantly highlyexpressed in cancer tissues such as invasive breast cancer,colon adenocarcinoma,and head and neck squamous cell carcinoma,and its expression in invasive breast cancer iscorrelated with tumor mutation burden;Further analysis found that there is a difference between the expression level of LncRNA BCAR4 in invasive breast cancer and some clinical stages of invasive breast cancer patients,that is,between stage I and stage II(P=0.015),between stage I and stage III(P=0.021)There is a difference in expression,but there is no statistical difference between other stages,and its expression level is negatively correlated with survival prognosis(P<0.05).2.LncRNA BCAR4 is significantly higher in locally advanced breast cancer tissues than inunpaired normal breast tissues,and its expression is positively correlated with the size oflocally advanced breast cancer tumors,and the expression is higher in HER-2 negativeversus HER-2 positive,And no significant correlation with age,hormone receptorstatus,Ki-67 and other pathological characteristics.3.Under the RECIST 1.1 evaluation system,the expression level of LncRNA BCAR4 is related to the efficacy of neoadjuvant chemotherapy for locally advanced breast cancer.The lower the expression,the better the efficacy(P<0.05);the Miller Payne evaluation system and histopathological evaluation system are used for evaluation There was nostatistical correlation between the expression of LncRNA BCAR4 and the efficacy of neoadjuvant chemotherapy.Conclusion:LncRNA BCAR4 is highly expressed in patients with locally advanced breast cancer,and has a significant negative correlation with the efficacy of neoadjuvant chemotherapy under the RECIST 1.1 evaluation system.Its expression can predict the clinical efficacy of neoadjuvant chemotherapy for locally advanced breast cancer to a certain extent.